New hope for rare bone cancer? drug shows promise in early trial

NCT ID NCT01267955

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This phase 2 trial tested vismodegib, a pill that targets a specific growth pathway, in 45 people with advanced chondrosarcoma (a rare bone cancer). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had to have measurable disease and no more than three prior chemotherapy treatments. The study used a two-stage design to decide if the drug was worth further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vismodegib (a targeted cancer drug taken by mouth)
What this could lead to: If it works, this could provide a new treatment option for people with advanced chondrosarcoma, a rare bone cancer that currently has few effective therapies.
What could go wrong: This is a small, early-phase trial with only 45 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects like muscle spasms, hair loss, and fatigue are common.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL CHONDROSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chondrosarcoma Chondrosarcoma, Clear Cell clear cell chondrosarcoma dedifferentiated chondrosarcoma mesenchymal chondrosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL CHONDROSARCOMA DEDIFFERENTIATED CHONDROSARCOMA LOCALLY ADVANCED CHONDROSARCOMA MESENCHYMAL CHONDROSARCOMA METASTATIC CHONDROSARCOMA PRIMARY CENTRAL CHONDROSARCOMA UNRESECTABLE PRIMARY CENTRAL CHONDROSARCOMA

Contacts and locations

Locations

Centre Leon Berard

Lyon, 69373, France
Centre Oscar Lambert

Lille, 59020, France
Gustave Roussy

Villejuif, 94805, France
Hopital De La Timone

Marseille, 13385, France
Institut Bergonie Cancer Center

Bordeaux, 33076, France
Institut Curie Paris

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.